Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses two studies investigating entrectinib in patients with advanced solid tumors.

Combined results were recently presented from the ALKA-372-001 study, which explored intermittent and continuous dosing of entrectinib, and the STARTRK-1 study, which looked at continuous dosing of the agent. In a safety analysis of 119 patients, entrectinib was found to be very well tolerated, Drilon says.

The majority of adverse events were grade 1/2 and included fatigue, changes in taste, and paresthesia. One of the longest responders enrolled on the study has been on treatment for 2 years and 3 months, Drilon adds.

Alexander Drilon, MD

Articles

Dr. Drilon on Entrectinib in Patients With Advanced Solid Tumors